急诊PCI替罗非班预防无复流的作用

The efficacy of tirofiban during primary percutaneous coronary intervention in the patients with acute coronary syndrome with no-reflow phenomenon

目的探讨急诊经皮冠状动脉介入治疗(PCI)替罗非班预防冠脉无复流的作用。方法回顾分析急诊PCI患者90例,根据PCI术前及术中是否使用替罗非班,分为替罗非班组50例(无复流3例,血流正常47例),对照组40例(无复流12例,血流正常28例),记录两组基础临床情况、观察两组患者术中无复流发生率。结果替罗非班组无复流发生率6%明显低于对照组30%,两组间差异有统计学意义(P<0.05)。结论急诊PCI加强抗血小板治疗能减少无复流的发生,提高手术的近期疗效。

Objective To assess the efficacy of tirofiban in the patients with Acute Coronary Syndrome who had no-reflow phenomenon after primary percutaneous coronary intervention.Methods From January 2009 to July 2010,according to exercise with or without tirofiban,the patients with acute coronary syndrome divided into Tirofiban group（n=50） and control group（n=40）.The Tirofiban group was given Tirofiban during surgery followed by 10μg/kg.The control group underwent routine PCI surgery without Tirofiban infusion.The basis of clinical records,the occurrence of no-reflow phenomenon of the two groups were observed in the patients with primary PCI.Results Compared with the control group,the incidences of no-reflow phenomenon were significantly decreased in the tirofiban group（P〈0.05）.Conclusion Enhancing anti-blood platelet therapy can effectively decrease the no-reflow phenomenon during primary PCI.